Mebendazol: A novel drug to be studied for metastatic Melanoma
Filed Under: Health & Science | Posted: 08/12/2008 at 12:07AM
Comments | Region: India
Most patients with metastatic melanoma fail to respond to available therapies, the discovery of a viable investigational treatment with an established safety profile is a diehard need in oncology. The prohibitive costs and long lead times typically are two requirements to discover new cancer medicines.
Effectively sidestepping these barriers, researchers at the NYU Cancer Institute and the Ronald O. Perelman Department of Dermatology promisingly screened a library of already approved drugs for activity against the most deadly form of skin cancer. They have identified mebendazole, a drug used globally to treat parasitic infections, as a novel investigational agent for the treatment of chemotherapy-resistant malignant melanoma.
Mebendazole, is sold as a generic drug and has been used since the 1970s to treat roundworm, hookworm, pinworm, whipworm, and other worm-based parasitic infections. Previous research has also shown it to have some anti-tumor activity in lung and adreno-cortical cancer.